Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.64 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.64 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.64 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29072142 | 1.00 | CA1 (0.64) | CA1CA2SIRT2SIRT1SIRT3 | |
| SCHEMBL29326176 | 0.96 | CA1 (0.60) | CA1CA2SIRT2SIRT1SIRT3 | |
| SCHEMBL29072085 | 0.91 | FOLH1 (0.76) | SIRT2SIRT1FOLH1HTTMMP2 | |
| SCHEMBL29072081 | 0.91 | FOLH1 (0.76) | SIRT2SIRT1FOLH1HTTMMP2 | |
| SCHEMBL18348898 | 0.91 | SIRT2 (0.72) | CA1CA2SIRT2SIRT1SIRT3 | |
| SCHEMBL15976615 | 0.90 | CA1 (0.66) | CA1CA2SIRT2SIRT1SIRT3 | |
| SCHEMBL29072115 | 0.89 | KLK7 (0.60) | CA1CA2FOLH1HTT | |
| SCHEMBL29072109 | 0.89 | KLK7 (0.60) | CA1CA2FOLH1HTT | |
| SCHEMBL15253875 | 0.89 | KLK7 (0.60) | CA1CA2SIRT2SIRT1SIRT3 | |
| SCHEMBL30823356 | 0.89 | CA1 (0.60) | CA1CA2SIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651901-A1 | CYCLING LYSOSOMAL TARGETING ANTIBODY CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025035040-A1 | LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES | LYCIA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| EP-4274582-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | Osprey Biopharmaceuticals, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-116744944-A | Low-immunogenicity biotherapeutic medicine | 奥斯普瑞生物制药有限公司 | 2023-09-12 | — | — | CN | disclosed |
| WO-2022150726-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | FCGR3B, CD47, IL2 | CA1 4539/4885CA2 4456/4885SIRT2 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.